Eclipse develops drug candidates, such as ET101 that targets cancer stem cells (CSCs), which are the seeds at the root of cancer.
Bionomics CEO and managing director Deborah Rathjen said the acquisition expands Bionomics’ oncology pipeline beyond BNC105, a primary cancer drug candidate.
”It also establishes Bionomics as a global leader at the forefront of cancer stem cell therapeutics," Rathjen added.
Bionomics with the expansion into the US is also expected to increase its small molecule and antibody programs profile.
Bionomics non-executive director Dr Lim said, "Eclipse shares Bionomics’ vision of building a world-class oncology franchise, and integrating our oncology assets with Bionomics strengthens our prospects for success based on their existing depth of oncology expertise and the ability to be part of a larger and highly motivated team."
Bionomics chairman Chris Fullerton said, "Despite difficult financial markets our company signed the ground-breaking US$345 million Ironwood anxiety therapy deal, expanded and accelerated our Kv1.3 program with new targets, initiated a BNC105ovarian cancer clinical trial and has now grabbed a foothold in a highly promising cancer stem cell technology."
&D Biologics vice president.